DHEA, intravaginal

Drug Overview

The menopausal transition brings about a variety of natural changes to a woman’s body. While hot flashes often receive the most attention, localized changes in the pelvic region can be equally, if not more, disruptive to a woman’s quality of life and intimate relationships. Within the Gynecology drug category, advanced treatments have been specifically developed to address these deeply personal concerns safely and effectively. Intravaginal DHEA is a groundbreaking prescription medication belonging to the Steroid Hormone (DHEA) drug class.

Operating as a highly specialized and localized Hormone Modulator, intravaginal DHEA offers a completely unique approach to treating menopausal vaginal changes. Unlike traditional hormone therapies that introduce active, circulating estrogens into the entire body, this medication provides an inactive precursor. Your body’s own cells absorb it and convert it locally into the exact amounts of hormones they need, restoring the natural health, thickness, and elasticity of vaginal tissues without significantly raising hormone levels in your bloodstream.

• Generic Name: Prasterone (synthetic dehydroepiandrosterone or DHEA)
• US Brand Names: Intrarosa
• Route of Administration: Intravaginal (administered as a small, daily waxy insert or suppository)
• FDA Approval Status: Fully FDA-approved for the treatment of moderate to severe dyspareunia (painful sexual intercourse), a hallmark symptom of vulvar and vaginal atrophy (VVA) due to menopause.

What Is It and How Does It Work? (Mechanism of Action)

Menopause causes a dramatic drop in ovarian estrogen and testosterone, leading to thin, dry, fragile vaginal walls—a condition called vulvar and vaginal atrophy (VVA). Intravaginal DHEA (prasterone) reverses this locally through intracrinology: the insert melts in the vaginal canal, and prasterone is absorbed into vaginal cells, where enzymes convert it into active estrogens and androgens.

These locally produced hormones bind to cellular receptors, stimulating DNA to rebuild vaginal thickness, restore glycogen for healthy vaginal pH, regenerate nerve density, and improve pelvic tissue tone and elasticity. Because the conversion occurs inside the cells, systemic hormone levels remain unaffected, the HPO axis is undisturbed, and the uterine lining is not stimulated, providing precise, localized therapy.

FDA-Approved Clinical Indications

This medication is utilized strictly within the scope of gynecological health to manage the localized physical symptoms of menopausal hormone deficiency.

Primary Gynecological/Obstetric Indications

• Dyspareunia (Painful Intercourse): The primary, FDA-approved indication is the treatment of moderate to severe pain during sexual intercourse resulting from menopausal vulvar and vaginal atrophy.
• Genitourinary Syndrome of Menopause (GSM): Serves as a foundational treatment for the broader category of GSM, actively reversing the underlying tissue thinning that causes daily vaginal burning, itching, and dryness.

Off-Label / Endocrinological Indications

• Vaginal Dryness (Without Painful Sex): Frequently prescribed off-label for postmenopausal women whose primary complaint is severe daily vaginal dryness and irritation, even if they are not sexually active.
• Mild Stress Urinary Incontinence: Used off-label to strengthen the pelvic tissues and musculature supporting the urethra, which can help reduce mild urinary leakage associated with postmenopausal tissue laxity.
• Lichen Sclerosus Adjunct: Occasionally utilized off-label as a supportive therapy alongside topical steroid creams to improve the elasticity and resilience of vulvar tissues affected by this chronic skin condition.

Dosage and Administration Protocols

Intravaginal DHEA is designed for ease of use and consistent, daily relief. It comes as a solid, bullet-shaped, waxy insert that is placed directly into the vagina.

Dose Adjustments and Special Populations:

• Hepatic and Renal Insufficiency: Because intravaginal DHEA is converted and metabolized locally within the vaginal tissues and does not significantly enter systemic circulation, no specific dose adjustments are required for patients with mild to moderate kidney or liver impairment.
• History of Breast Cancer: While this medication does not raise systemic estrogen levels above normal postmenopausal ranges, it has not been extensively studied in women with a history of breast cancer. It should only be used in this patient population after a careful, personalized consultation with the patient’s oncologist.

Clinical Efficacy and Research Results

Clinical data (2020–2026) confirms intravaginal DHEA (6.5 mg prasterone) effectively restores vaginal health and sexual function. Within 12 weeks, the Vaginal Maturation Index shows a 40–50% decrease in immature parabasal cells and a 10–15% increase in healthy superficial cells, while vaginal pH normalizes below 4.5. Symptomatically, dyspareunia improves by >1.5 points on a 3-point VAS, and over 80% of patients report comfortable, pleasurable intercourse within 3–6 months, significantly enhancing quality of life.

Safety Profile and Side Effects

Unlike traditional vaginal estrogen creams and tablets, which carry a mandated FDA Black Box Warning for cardiovascular disorders and endometrial cancer risks, intravaginal DHEA notably does not carry a boxed warning. This reflects its unique safety profile and its scientifically proven ability to keep active hormone levels safely contained within the vaginal tissues without stimulating the endometrium.

Common Side Effects (Occurring in more than 10 percent of patients)

• Vaginal Discharge: The most frequently reported side effect is a noticeable increase in vaginal discharge. This is entirely normal and is simply the result of the natural hard fat (the waxy base) of the insert melting and naturally clearing from the body overnight.
• Abnormal Pap Smear: A very small percentage of women may experience temporary, atypical cervical cell readings on a routine Pap smear as the tissues rapidly regenerate and change.

Serious Adverse Events and Management Strategies

• Undiagnosed Genital Bleeding: The medication is absolutely contraindicated in women with active, undiagnosed, or abnormal vaginal bleeding. Any unexpected postmenopausal bleeding must be thoroughly investigated to rule out uterine cancer before starting this therapy.
• Management Strategies: To manage the increased vaginal discharge caused by the melting insert, patients are highly advised to use the medication right before going to sleep and to wear a breathable cotton panty liner overnight. If any unexpected vaginal spotting occurs, the patient must stop the medication and contact their gynecologist immediately for a pelvic ultrasound.

Connection to Stem Cell and Regenerative Medicine

Recent research (2023–2026) highlights intravaginal DHEA as a “tissue priming” therapy in regenerative gynecology. Daily use for 4–8 weeks thickens, hydrates, and vascularizes vaginal walls before PRP, mesenchymal stem cell, or Fractional CO₂ Laser treatments. By improving local blood flow, cellular readiness, and mucosal health, without systemic estrogen, this targeted therapy enhances engraftment, healing, and long-term success of advanced regenerative procedures.

Disclaimer: The information presented regarding the use of intravaginal DHEA in regenerative gynecology, including its role as a tissue-priming agent alongside therapies such as PRP, stem cells, or laser treatments, is based on emerging and exploratory research. These applications are not yet fully validated through large-scale clinical trials and are not part of established standard medical practice or approved clinical indications. Therefore, such findings should be interpreted with caution and are not currently applicable to routine clinical or professional treatment settings.

Patient Management and Practical Recommendations

Effective patient management ensures that the life-changing benefits of this localized therapy are maximized while keeping the patient comfortable, safe, and well-informed.

Pre-Treatment Tests

• Pelvic Exam and Pap Smear: A comprehensive clinical gynecological exam is necessary to visually confirm the diagnosis of atrophy, evaluate the vaginal mucosa, and rule out other underlying pelvic infections.
• Mammogram: Routine, age-appropriate breast cancer screenings should be up to date before initiating any hormone-related therapy, even localized ones.
• Medical History: A thorough review to ensure the patient has no history of unexplained postmenopausal vaginal bleeding or active, hormone-sensitive malignancies.

Precautions During Treatment

• Barrier Contraception Weakening: The waxy, fat-based ingredients used to formulate the DHEA insert can weaken and break down latex or rubber products. Polyurethane condoms or alternative non-latex barriers must be used, as traditional latex condoms and vaginal diaphragms may fail and break if used alongside this medication.
• Partner Exposure: Because the medication converts to active hormones entirely inside your own vaginal cells, there is virtually no risk of transferring active hormones to your sexual partner, making it highly safe for intimate contact.

“Do’s and Don’ts” list

• DO insert the medication strictly at bedtime while lying down to ensure the melted medication stays in the vaginal canal and fully coats the tissues.
• DO use the disposable applicators provided in the package, and discard each applicator after a single use to maintain strict pelvic hygiene.
• DO wear a cotton panty liner overnight to protect your undergarments from the harmless waxy discharge.
• DON’T use the insert if you are experiencing active, undiagnosed vaginal bleeding.
• DON’T stop using the medication simply because your symptoms improve. Vulvar and vaginal atrophy is a chronic, progressive condition; if you stop the medication, the pain and dryness will eventually return.
• DON’T worry about severe systemic side effects like weight gain or mood swings, as this highly targeted therapy stays safely and securely within your vaginal tissues.

Legal Disclaimer

The medical information provided in this comprehensive guide is intended solely for educational and informational purposes and does not constitute professional medical advice, diagnosis, or treatment. Every patient’s medical history is unique. Always seek the direct advice of your physician, gynecologist, or other qualified healthcare provider regarding any questions you may have about a medical condition, menopausal symptoms, or before starting, stopping, or altering any prescribed medication regimen.